Nitazoxanide for chronic hepatitis C

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 4, 2014, Pages

  Nikolova, Kristiana ^a   Gluud, Christian ^a   Grevstad, Berit ^a   Jakobsen, Janus C ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; NITAZOXANIDE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; TELAPREVIR; ANTIVIRUS AGENT; THIAZOLE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALL CAUSE MORTALITY; ANEMIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS C; COMBINATION DRUG THERAPY; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; LOW DRUG DOSE; MONOTHERAPY; NEUTROPENIA; PRIORITY JOURNAL; RELAPSE; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ADULT; BLOOD; CAUSE OF DEATH; HEPATITIS C, CHRONIC; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; CAUSE OF DEATH; HEPATITIS C, CHRONIC; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLES;

EID: 84942784552     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009182.pub2     Document Type: Review

References (138)

1. Bacon B, Shiffman M, Lim J, Berman A, Rustgi V, Keeffe E. A phase II, randomized, double-blind, placebo-controlled study of nitazoxanide plus peginterferon and ribavirin in naive patients with chronic hepatitis C genotype 1 infection: final report. Gastroenterology 2010;139(1):e18.
2. Bacon B, Shiffman M, Lim J, Berman A, Rustgi V, Keeffe E. Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide plus peginterferon and ribavirin in HCV genotype 1 naive patients: week 12 sustained virological response rate. Journal of Hepatology 2010;52(Suppl 1):S3.
3. Bacon B, Shiffman M, Lim J, Berman A, Rustgi V, Keeffe E. Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide plus peginterferon and ribavirin in HCV genotype 1 patients: interim analysis shows increase in EVR. Journal of Hepatology 2009;50(Suppl 1):S381.
4. Berrie C. Combined thiazolide nitazoxanide plus PEG-IFN Alfa-2a/ribavirin improved viral response in HCV genotype 1: presented at EASL 2010. http://www.firstwordpharma.com/node/604408?tsid=17#axzz2y2MTgiDa (accessed 4.04.2014).
5. NCT00637923. Study of nitazoxanide, peginterferon alfa-2a and ribavirin in treatment-naive hepatitis C patients (STEALTH-3). http://clinicaltrials.gov/show/NCT00637923 (accessed 24 January 2014).
6. Basu P, Nair T, Farhat S, Ang L, Jafri M, Mittimani K, et al.Pegylated interferon alfa, nitazoxanide, telapravir, ribavirin, in genotype 1 undergoing prior experienced chronic hepatitis C patients-a randomized placebo control clinical pilot trial (INTRIGUE C) interim. Hepatology International 2012; Vol. 22nd Conference of the Asian Pacific Association for the Study of the Liver, APASL 2012 Taipei Taiwan:64. [CRS-ID: 6800100000029745].
7. Basu P, Nair T, Farhat S, Ang L, Mittimani K, Shah NJ, et al.Peg-interferon alfa, nitazoxanide, telapravir, ribaverin, in genotype 1 in treatment experienced chronic hepatitis C patients - a randomized control pilot trial. Journal of Gastroenterology and Hepatology 2012; Vol. 27, issue S5:207. [CRS-ID: 6800100000029736].
8. Basu P, Shah N, Farhat S, Siriki R, Rahman M, Lynn A, et al.Pegylated interferon alfa, nitazoxanide, telaprevir, ribavirin, in genotype 1 undergoing prior experienced chronic hepatitis C patients - a randomized placebo control clinical pilot trial (intrigue-C). American Journal of Gastroenterology 2012; Vol. 107, issue S1:S154. [CRS-ID: 6800100000029740].
9. Basu P, Shah N, Farhat S, Siriki R, Rahman MD, Lynn A, et al.Pegylated interferon alfa, nitazoxanide, telaprevir, ribavirin, in genotype 1 undergoing prior experienced chronic hepatitis C patients - a randomized placebo control clinical pilot trial (INTRIGUE-C) Interim. American Journal of Gastroenterology 2012; Vol. 142, issue 5:S932. [CRS-ID: 6800100000029788].
10. Keeffe EB, Elfert A, Abousaif S, Rossignol J. Controlled release nitazoxanide in combination with peginterferon alfa-2a plus ribavirin results in high early virologic response rates for treatment of chronic hepatitis C genotype 4. Hepatology 2009; Vol. 50, issue 4 (Suppl):1038A.
11. Keeffe EB, Elfert AA, Abousaif SA. Dose-related increase in virologic responses using controlled release nitazoxanide plus peginterferon alfa-2A and ribavirin for treatment of chronic hepatitis C genotype 4: final report. Journal of Hepatology 2011;54(Suppl 1):S479-80.
12. Kabil SM, Soliman MS, Youssef SM, Mounier BI. A controlled study of nitazoxanide (NTZ) 3 years after treatment of hepatitis C genotype 4. Journal of the Egyptian Society of Parasitology 2011;41(2):251-61.
13. Rossignol JF, Kabil SM, El-Gohary Y, Keeffe EB. Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Alimentary Pharmacology & Therapeutics 2008; Vol. 28:574-80.
14. Rossignol JF, Kabil SM, El-Gohary Y, Keeffe EB. Randomized double blind placebo-controlled trial of nitazoxanide in the treatment of patients with chronic hepatitis C genotype 4 [abstract]. Journal of Hepatology 2008;48(Suppl 2):S311-2.
15. Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 2009;136(3):856-62.
16. Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB. Randomized controlled trial of nitazoxanide-peginterferonribavirin, nitazoxanide-peginterferon and peginterferon-ribavirin in the treatment of patients with chronic hepatitis C genotype 4. Journal of Hepatology 2008;48(Suppl 2):S30.
17. Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB, Glenn J. Interim data from a randomized controlled trial of nitazoxanide-peginterferon-ribavirin, nitazoxanide-peginterferon and peginterferon-ribavirin in the treatment of patients with chronic hepatitis C genotype 4. Hepatology 2007;46(4 Suppl 1):316A-317A.
18. NCT01276756. Efficacy of nitazoxanide in the treatment of chronic hepatitis C virus (HCV). http://clinicaltrials.gov/ct2/show/NCT01276756?term=Efficacy+of+nitazoxanide+in+the+treatment+of+chronic+hepatitis+C+virus+%28HCV%29&rank=1 (accessed 24 January 2014). [: NCT01276756].
19. Shehab H [pers comm]. Efficiacy of nitazoxanide in the treatment of chronic hepatitis C virus (HCV). By email 28.11.2012.
20. Shehab H, Elbaz T, Draz D. The addition of nitazoxanide to pegylated interferon and ribavirin does not improve SVR rates in chronic HCV genotype 4. Journal of Hepatology 2013; Vol. 58, issue Suppl 1:495.
21. NCT00495391. Study of nitazoxanide, peginterferon alfa-2a and ribavirin for the treatment of hepatitis c (STEALTH-2). http://clinicaltrials.gov/ct2/show/NCT00495391?term=NCT00495391&rank=1 (accessed 24 January 2014).
22. Shiffman M, Ahmed A, Jacobson I, Pruitt R, Keeffe E. Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide with peginterferon alfa-2A and ribavirin in nonresponders (NR) with chronic HCV genotype 1: week 28 interim analysis. Journal of Hepatology 2009; Vol. 50, issue Suppl 1:S385.
23. Shiffman ML, Ahmed A, Jacobson IM, Pruitt RE, Keeffe EB. Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide with peginterferon alfa-2a and ribavirin in nonresponders (NR) with chronic hepatitis C genotype 1: final report. Journal of Hepatology 2010;52(Suppl 1):S459-S71.
24. Asrani SK, Anderson S, Wilson J, Myhre LJ, Heimbach J, Kremes WK, et al.Nitazoxanide for the prevention of recurrent hepatitis C virus infection after liver transplantation: A pilot study. Hepatology 2010;52(S1):874A.
25. Basu P, Rayapudi K, Shah NJ, Krishnaswamy N, Pacana T, Khemani J, et al.Effects of high dose ribavirin (RBV), alinia (nitazoxanide) and pegylated Interferon (peg) alfa-2a in attaining sustained viral response (SVR) in treatment of chronic hepatitis C (ERAIS-C Trial) - interim results in naive genotype 1 patients. Hepatology 2009; Vol. 50, issue 4:730A-1A. [CRS-ID: 6800100000029790].
26. Basu P, Rayapudi K, Shah NJ, Pacana T, Krishnaswamy N, Brown R. Effect of high-dose ribavirin (RBV), alinia (nitazoxanide) and pegylated Interferon (pegifn) alfa-2a in attaining sustained virologic response (SVR) in treatment of chronic hepatitis C. Journal of Hepatology 2010; Vol. 52, issue S1:S102. [CRS-ID: 6800100000029779].
27. Basu PP, Rayapudi K, Pacana T, Shah NJ, Brown R. Effects of high dose ribavirin, alinia (R) (nitazoxanide) and pegylated interferon alfa-2a in attaining sustained viral response in treatment of chronic hepatitis C (ERAIS-C Trial) - interim results in naive genotype 1 patients. American Journal of Gastroenterology 2009;104(Suppl 3):S125.
28. Basu PP, Rayapudi K, Pacana T, Shah NJ, Krishnaswamy N, Brown RS. Effect of high-dose ribavirin (RBV), alinia (nitazoxanide) and pegylated interferon (pegIFN) alfa-2a in attaining sustained virologic response (SVR) in treatment of chronic hepatitis C (ERAIS-C Trial) in naïve genotype 1 patients. International Journal of Infectuous Diseases 2010;14(S2):S1-S2.
29. Basu PP, Rayapudi K, Pacana T, Shah NJ, Krishnaswamy N, Brown RS. Effects of high-dose ribavirin (RBV), alinia (nitazoxanide) and pegylated interferon (pegIFN) alfa-2a in attaining sustained virological response (SVR) in treatment of chronic hepatitis C (ERAIS-C trial) in naive genotype 1 patients. Gastroenteology 2010;138(5):S-218.
30. Kamal SM. Hepatitis C virus genotype 4 therapy: progress and challenges. Liver International 2011; Vol. 31, issue Suppl 1:45-52.
31. Kanda T, Imazeki F, Yokosuka O. New antiviral therapies for chronic hepatitis C. Hepatology International 2010; Vol. 4, issue 3:548-61.
32. Keeffe EB. Future treatment of chronic hepatitis C. Antiviral Therapy 2007; Vol. 12, issue 7:1015-25.
33. Keeffe EB, Rossignol JF, Elfert A, Abdelatif S, Cravens L, Phuong TLT. Controlled release tablet improves pharmacokinetics, viral kinetics and tolerability of nitazoxanide for treatment of chronic hepatitis C. 19th Conference of the Asian Pacific Association for the Study of the Liver, Hong Kong, China. Hepatology International 2009;3:34-69.
34. Keeffe EB. Current research on nitazoxanide in the treatment of chronic hepatitis C. Gastroenterology and Hepatology 2009; Vol. 5, issue 9:620-2.
35. Mederacke I, Wedemeyer H. Nitazoxanide for the treatment of chronic hepatitis C New opportunities but new challenges?. Annals of Hepatology 2009; Vol. 8, issue 2:166-8.
36. Parfieniuk A, Flisiak R. New perspectives in treatment of chronic hepatitis C [Nowe mozliwosci leczenia przewleklych zakazen HCV]. Gastroenterologia Polska 2009; Vol. 16, issue 4:329-32.
37. Pockros PJ. Emerging therapies for chronic hepatitis C virus. Gastroenterology and Hepatology 2008; Vol. 4, issue 10:729-34.
38. Pockros PJ, Balart LA. Advances in hepatology research. Reviews in Gastroenterological Disorders 2008; Vol. 8, issue 3:194-212.
39. Pockros PJ. Emerging therapy for chronic hepatitis C: Highlights from the 59th Annual Meeting of the American Association for the Study of Liver Diseases, 31 October-4 November 2008, San Francisco, CA. Reviews in Gastroenterological Disorders. 2009; Vol. 9, issue 1:27-34.
40. Rossignol JF, Keeffe EB. Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C. Future Microbiology 2008; Vol. 3, issue 5:539-45. [CRS-ID: 6800100000028352; JC--NLM: Journal ID:101278120].
41. Rossignol JF, Elfert A, Keeffe EB. Evaluation of a 4 week lead-in phase with nitazoxanide (NTZ) prior to peginterferon (pegifn) plus NTZ for treatment of chronic hepatitis C: final report. Hepatology 2008; Vol. 48, issue 4:1132A-1133A. [CRS-ID: 6800100000029791].
42. Rossignol JF, Elfert A, Keeffe EB. Evaluation of a 4-week lead-in with nitazoxanide (NTZ) prior to peginterferon (PegIFN) plus NTZ for treatment of chronic hepatitis C. Journal of Clinical Gastroenterology 2010; Vol. 44, issue 7:504-9. [DOI:; PUBMED: 20048684].
43. Rossignol JF, Elfert A, Keeffe EB. Evaluation of a 4-week lead-in with nitazoxanide (NTZ) prior to peginterferon (PegIFN) plus NTZ for treatment of chronic hepatitis C: final report. Hepatology 2008; Vol. 48, issue Suppl:1132A-3A.
44. Yoffe B, Gasitashvili K, Khaoustov V. Interim results: single center pilot efficacy study of nitazoxanide plus pegylated alpha-2a interferon and ribavirin in prior genotype 1 nonresponders with HCV induced cirrhosis. Journal of Hepatology 2009;50(Suppl 1):S353.
45. Yoffe B, Gasitashvili K, Khaoustov V. Pilot study of lead-in nitazoxanide plus pegylated alpha-2a interferon and ribavirin in HCV-genotype 1 nonresponders with cirrhosis: Interim results. Hepatology 2009;50(S4):1034A.
46. Kohla M, EL-Said H, El-Fert AY, Ehsan N, Ezzat S, Taha HA. Impact of nitazoxanide on early virologic response (EVR) in Egyptian patients with chronic hepatitis C genotype 4: a double blind placebo-controlled trial. Hepatology 2012; Vol. 56, issue S1:583A. [CRS-ID: 6800100000029739].
47. Kohla M, El-Said H, El-Fert A, Ehsan N, Ezzat S, Taha H. Impact of nitazoxanide on rapid virologic response in patients with chronic hepatitis C genotype 4: a double blind placebo-controlled trial. Journal of Gastroenterology and Hepatology 2012; Vol. 27, issue S5:236. [CRS-ID: 6800100000029735].
48. NCT01197157. Study of the impact of nitazoxanide on chronic hepatitis patients. http://clinicaltrials.gov/ct2/show/NCT01197157?term=NCT01197157&rank=1 (accessed 24 January 2014).
49. Altman D, Bland M. Interaction revisited: the difference between two estimates. BMJ (Clinical Research Ed.) 2003;326:219.
50. Aman W, Mousa S, Shiha G, Mousa SA. Current status and future directions in the management of chronic hepatitis C. Virology Journal 2012;9:57.
51. Amon JJ, Garfein RS, Ahdieh-Grant L, Armstrong GL, Ouellet LJ, Latka MH. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clinical Infectious Diseases 2008;46(12):1852-8.
52. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al.Boceprevir for previously treated chronic HCV genotype 1 infection. New England Journal of Medicine 2011;364:1207-17. [DOI:].
53. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology 2008;61(8):763-9.
54. Brok J, Gluud LL, Gluud C. Ribavirin monotherapy for chronic hepatitis C. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI:].
55. Brok J, Gluud LL, Gluud C. Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI:].
56. Bown JL. Interferon therapy reduces the risk for hepatocellular carcinoma. Gut 2000;47:610-611. [DOI:].
57. Chutaputti A. Adverse effects and other safety aspects of the hepatitis C antivirals. Journal of Gastroenterology and Hepatology 2000;15(Suppl E):156-63. [PUBMED: 10921400].
58. Copenhagen Trial Unit. TSA - Trial Sequential Analysis. ctu.dk/tsa/ 2011 (accessed 4 September 2013).
59. Davis GL. Hepatitis C virus genotypes and quasi species. American Journal of Medicine 1999;107(6B):21S-26S.
60. DeMets DL. Methods of combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341-50.
61. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
62. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629-34.
63. Everson GT, Sims KD, Rodriguez-Torres M, Hézode C, Lawitz E, Bourlière M, et al.Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 2014;146(2):420-9. [DOI:].
64. US Food, Drugs Administration. Drug development guidelines for Hepatitis C virus. http://www.fda.gov/drugs/newsevents/ucm385395.htm (accessed 23 February 2014).
65. Foster G, Uddin G, Dias A. Hepatitis C virus. In: Mahtab MA, Rahman S editor(s). Liver. A Complete Book on Hepato-Pancreato-Biliary Diseases. Elsevier. Health Sciences Education, 2009:229-44.
66. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine 2002;347:975-82.
67. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. Journal of Hepatology 2011;55:69-75.
68. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49(4):1335-74.
69. Gluud C, Nikolova D. Quality assessment of reports on clinical trials in the Journal of Hepatology. Journal of Hepatology 1998;29(2):321-7.
70. Gluud C. Evidence based medicine in LIVER. Liver 1999;19(1):1-2.
71. Kjaergard LL, Frederiksen SL, Gluud C. Validity of randomized clinical trials in Gastroenterology from 1964 to 2000. Gastroenterology 2002;122(4):1157-60.
72. Gluud C. The culture of designing hepato-biliary randomised trials. Journal of Hepatology 2006;44(1):607-15.
73. Gluud C, Brok J, Gong Y, Koretz RL. Hepatology may have problems with putative surrogate outcome measures. Journal of Hepatology 2007;46(4):734-42.
74. Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al.Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2013, Issue 12. Art. No.: LIVER.
75. Gurusamy KS, Wilson E, Koretz RL, Allen VB, Davidson BR, Burroughs AK, et al.Is sustained virological response a marker of treatment efficacy in patients with chronic hepatitis C viral infection with no response or relapse to previous antiviral intervention?. PLoS One 2013;8(12):e83313. [DOI:].
76. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al.Peginterferon alfa-2a (40 kilodaltons) and ribavirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Annals of Internal Medicine 2004;140:346-55.
77. Hauser G, Awad T, Brok J, Thorlund K, Štimac D, Mabrouk M, et al.Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C. Cochrane Database on Systematic Reviews 2014 (to be published). [DOI:].
78. Hauser G, Awad T, Thorlund K, Štimac D, Mabrouk M, Gluud C. Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C. Cochrane Database of Systematic Reviews 2014 (to be published). [DOI:].
79. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
80. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
81. Hodgson HJF. Viral hepatitis - clinical aspects. In: Warrell DA, Cox TM, Firth JD, Benz EJ Jr editor(s). Oxford Textbook of Medicine. 5th Edition. Oxford/ New York: Oxford University Press, 2003:http://otm.oxfordmedicine.com/cgi/content/essentials/5/1/med-9780199204854-chapter-152101.
82. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ (Clinical Research Edition) 1999;319:670-4.
83. International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines. Vol. 1, Pennsylvania, USA: Barnett International/PAREXEL, 1997.
84. Jacobson IM, McHutchison JG, Dusheiko G. Original article telaprevir for previously untreated chronic hepatitis C virus infection. New England Journal of Medicine 2011;364:2405-16. [DOI:].
85. Jakobsen JC, Gluud C. The necessity of randomized clinical trials. British Journal of Medicine and Medical Research 2013;3(4):1453-68.
86. Kabil SM, Soliman MS, Youssef SM, Mounier BI. A controlled study of nitazoxanide (NTZ) 3 years after treatment of hepatitis C genotype 4. Journal of the Egyptian Society of Parasitology 2011;41(2):251-61.
87. Kjaergard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between small and large randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
88. Kong Y, Wang X, Shang Y, Schroder PM, Liang W, Ling X, et al.Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis. PLoS ONE 2012;7(12):e52158.
89. Korba B, Montero A, Farrar K, Gaye K, Mukerjee S, Ayers M, et al.Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Research 2008;77(1):56-63.
90. Korba BE, Elazar M, Lui P, et al.Potential role for nitazoxanide in combination with STAT-C agents for the inhibition of HCV replication without the development of resistance. Hepatology 2008;48(Suppl):356A.
91. Koretz RL, Pleguezuelo M, Arvaniti V, Barrera Baena P, Ciria R, Gurusamy KS, et al.Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI:].
92. Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, et al.Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013;381(9883):2100-7. [DOI:].
93. Lauer GM, Walker BD. Hepatitis C virus infection. New England Journal of Medicie 2001;345(1):41-52.
94. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al.Sofosbuvir for previously untreated chronic hepatitis C Infection. The New England Journal of Medicine May 2013;368:1878-87. [DOI:].
95. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI:].
96. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358(9286):958-65.
97. McKenzie CF. Current therapies for chronic hepatitis C. Pharmacotherapy 2011;31(1):92-111.
98. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352:609-13.
99. Myers RP, Regimbeau C, Thevenot T, Leroy V, Mathurin P, Opolon P, et al.Interferon for interferon naive patients with chronic hepatitis C. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI:].
100. National Institutes of Health. Chronic hepatitis C: current disease management. http://digestive.niddk.nih.gov/ddiseases/pubs/chronichepc/ 2010 (accessed December 2010).
101. United Network for Organ Sharing. 2005 OPTN/SRTR Annual Report (Chapter VI; Liver and Intestine Transplantation in the United States, 1995-2004). http://optn.transplant.hrsa.gov/ar2009/ar_archives.htm 2005 (accessed January 2011).
102. Ortiz JJ, Ayoub A, Gargala G, Chegne NL, Favennec L. Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from Northern Peru. Alimentary Pharmacology & Therapeutics 2001;15(9):1409-15. [DOI:].
103. Pankuch GA, Appelbaum PC. Activities of tizoxanide and nitazoxanide compared to those of five other thiazolides and three other agents against anaerobic species. Antimicrobial Agents and Chemotherapy 2006;50(3):1112-7.
104. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky J. Structural biology of hepatitis C virus. Hepatology 2004; Vol. 39, issue 1:5-19. [DOI:].
105. Poordad F, McCone, J, Bacon BR, Bruno S, Michael MP, Sulkowski MS, et al.Boceprevir for untreated chronic HCV genotype 1 infection. New England Journal of Medicine 2011;364:1195-206. [DOI:].
106. Reddy CRMB, Subbareddy GV. Study and improvement of spectrophotometric and HPLC methods for the determination of nitazoxanide in pharmaceutical preparations. Journal of Chemical and Pharmaceutical Research 2012;4(7):3708-14. [: ISSN: 0975-7384].
107. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
108. Rosenberg S. Recent advances in the molecular biology of hepatitis C virus. Journal of Molecular Biology 2001;313:451-64.
109. Rossignol JF, Hidalgo H, Feregrino M, Higuera F, Gomez WH, Romero JL, et al.A double-b placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in aids patients in Mexico. Transactions of the Royal Society of Tropical Medicine and Hygiene 1998;92(6):663-6. [DOI: ;:].
110. Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide. Journal of Infectious Diseases 2001;184(1):103-6.
111. Rossignol JF. Thiazolides: a new class of antiviral drugs. Expert Opinion on Drug Metabolism & Toxicology 2009;5(6):667-74.
112. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
113. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al.Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157:429-38.
114. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al.Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment 2012;16(35):1-82.
115. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
116. Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Internal Journal of Surgery 2011;9(8):672-7.
117. Seeff LB, Hoofnagle JH. National Institutes of Health consensus development conference: Management of hepatitis C: 2002. Hepatology 2002; Vol. 36:S1-S2. [DOI:].
118. Sherman KE, Flamm SL, Afdhal NH. Response-guided telaprevir combination treatment for hepatitis C virus infection. New England Journal of Medicine 2011;365:1014-24. [DOI:].
119. Sitole M, Silva M, Spooner L, Comee MK, Malloy M. Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials. Clinical Therapeutics February 2013;35(2):190-7. [DOI:].
120. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. Centers for Disease Control and Prevention 2012;61(RR04):1-18.
121. Soza A, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K, et al.Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002;36(5):1273-9. [PUBMED: 12395340].
122. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al.SPIRIT 2013 Statement: defining standard protocol items for clinical trials. Annals of Internal Medicine 2013;158:200-7.
123. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, et al.SPIRIT 2013 Explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586.
124. Stockis A, Allemon AM, De Bruyn S, Gengler C. Nitazoxanide pharmacokinetics and tolerability in man using single ascending oral doses. International Journal of Clinical Pharmacology and Therapeutics 2002;40:213-20.
125. Strader DB, Wright T, Thomas LD, Seeff LB. AASLD practice guideline: diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39(4):1147-71.
126. Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. Journal of Viral Hepatitis 2004;11(3):243-50. [PUBMED: 15117326].
127. Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al.Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses. International Journal of Epidemiology 2009;38(1):276-86.
128. Thorlund K, Anema A, Mills E. Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. Clinical Epidemiology 2010;2:57-66.
129. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual forTrial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 23 April 2013).
130. van Regenmortel MHV, Fauquet CM, Bishop DHL, Carstens EB, Estes MK, Lemon SM, et al.Virus Taxonomy: Seventh Report of the International Committee on Taxonomy of Viruses. San Diego: Academic Press, 2000.
131. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75.
132. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology 2009;9:86.
133. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61:64-75.
134. World Health Organization. Viral hepatitis. Report by the secretariat. apps.who.int/gb/ebwha/pdf_files/WHA63/A63_15-en.pdf 2010 (accessed January 2011).
135. World Health Organiziation. Hepatitis C. Fact sheet No. 164. http://www.who.int/mediacentre/factsheets/fs164/en/index.html 2011; Vol. (accessed 24 January 2014).
136. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al.Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601-5.
137. Yang D, Liang HJ, Li D, Wei X, Ma L, Jia Z. The efficacy and safety of telaprevir-based regimens for treating chronic hepatitis C virus genotype 1 infection: a meta-analysis of randomized trials. Internal Medicine 2013;52(6):653-60.
138. Zeuzem S, Andreone P, Pol S. Telaprevir for retreatment of HCV infection. New England Journal of Medicine 2011;364:2417-28. [DOI:].